Search clinical trials for: PegIntron (peginterferon alfa-2b; SCH 54031)

Total 317 results

University of Michigan Rogel Cancer Center

Terminated

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States
Merck Sharp & Dohme LLC

Terminated

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Chronic Hepatitis C (CHC)
PharmaEssentia Japan K.K.
PharmaEssentia

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

Australia
Fang Wang

Recruiting

A Study on Antiviral Treatment of Chronic Hepatitis B in Children

Chronic HBV Infection

China
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Childhood Craniopharyngioma

United States
Guangzhou 8th People's Hospital

Recruiting

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Hepatitis B | AIDS

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Hepatitis B, Chronic

China
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

HIV Infection

United States
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)

Hepatitis C

United States, France, Poland, Belgium, Germany, Spain, Portugal, Bulgaria, Turkey, Argentina, Brazil, Austria, Netherlands, Slovakia, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)

Hepatitis C, Chronic
PharmaEssentia

Not yet recruiting

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera (PV)

Polycythemia Vera | Myeloproliferative Neoplasm
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
Hoffmann-La Roche

Completed

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Hepatitis C, Chronic

Brazil
National Taiwan University Hospital

Recruiting

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

Pre-fibrotic Myelofibrosis

Taiwan
PharmaEssentia

Recruiting

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Essential Thrombocythemia

United States, Canada
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

Chronic Hepatitis C
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
The Immunobiological Technology Institute (Bio-Manguinhos)...
Hospital de Clinicas de Porto Alegre

Unknown

BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (BIP48II/III)

Chronic Hepatitis C

Brazil
FGK Clinical Research GmbH
University Hospital, Saarland

Completed

Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

Hepatitis C, Chronic

Germany
Hepatitis Resource Network
Hoffmann-La Roche

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Chronic Hepatitis C Virus Infection

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC

Terminated

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Myelofibrosis

United States
Merck Sharp & Dohme LLC

Completed

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

Liver Transplantation | Liver Cirrhosis | Hepatitis C, Chronic
Xiamen Amoytop Biotech Co., Ltd.

Completed

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Chronic Hepatitis C

China
BioWest Therapeutics Inc

Unknown

A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Chronic Hepatitis C

Canada
Qing XIe

Recruiting

A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Chronic Hepatitis B | Intermediate to High Risk of HCC

China
The Wistar Institute
University of Pennsylvania; Merck Sharp & Dohme LLC

Completed

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

HIV-1 Infection

United States
PharmaEssentia

Completed

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Chronic Hepatitis C Virus Infection

Korea, Republic of, Taiwan, China
Hassane M. Zarour, MD
Merck Sharp & Dohme LLC; Melanoma Research Alliance

Completed

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Melanoma

United States
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Merck Sharp & Dohme LLC

Withdrawn

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Hepatitis B
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Chronic Hepatitis C

Japan
Fuzhou General Hospital

Recruiting

Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia

China
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Hepatitis C Infection

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Hepatitis C

Japan
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Medtronic Corporate Technologies and New Ventures

Completed

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C (COPE-HCV)

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

Hepatitis C, Chronic
Vertex Pharmaceuticals Incorporated
Janssen Pharmaceuticals

Terminated

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Hepatitis C

United States, United Kingdom, Spain, Belgium, Italy, Germany
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C

Chronic Hepatitis C

Egypt
Merck Sharp & Dohme LLC

Completed

Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)

Hepatitis C, Chronic | Hepatitis C Virus
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
Qin Ning

Unknown

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV)

Chronic Hepatitis b
Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic

3

Subscribe